Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Ewing's family of tumors

• Current disease state for which there is no curative therapy

Exclusion Criteria:

• Prior anti-IGF-1R therapy

• Concurrent treatment with other anti-cancer agents